Erythropoietic Protoporphyria (EPP) and X-Linked Protoporphyria (XLP) are inherited disorders of heme metabolism resulting in the building of the immediate precursor to heme, a molecule called Protoporphyrin IX (PPIX). Once in circulation, PPIX drives painful skin photosensitivity, liver injury, and damage in other tissues.
Our approach is to directly remove PPIX from circulation using our proprietary porphyrin-scavenging technology. By removing this disease-causing molecule, we hope to create a potent disease-modifying treatment for patients.
We are developing heme-sequestering proteins for indications driven by excess free heme, including kidney injury, hemolysis, and cancer.